

Tsukiji Translational Research Board (TTRB)



国立研究開発法人
国立がん研究センター
National Cancer Center Japan

Tsukiji TR Board (TTRB)'s Goal

Purpose : Translational Research (TR) acceleration globally

- Engage and commit to accelerate TR globally by leveraging broad knowledge, technologies and experienced expertise across NCC Hospital (NCCH) and NCC Research Institute (NCCRI), co-located at Tsukiji Campus.
- Provide an easy access for Pharma, Bio-Tech, Bio-Venture and Academia to consult with NCCH and NCCRI for TR strategy and collaboration.
- Support customers to conduct a strategic drug development from non-clinical to clinical for ensuring a seamless development in global and including Japan.

Focus : Every type of TR including reverse TR

【Best case of collaboration】

1. Validate MoA/target indication of a projects under a discovery phase
2. Strategic planning and carrying out of non-clinical studies
3. Discovering a potential biomarker to be used for clinical studies
4. Effective implementation of Global FIH studies (from Dose Escalation) at NCC Japan.

Seamless
support



Consultation fee : Free

TTRB collaboration opportunities



TR collaboration with Pharma/Bio-Tech/ Bio-Venture

- Basic research collaboration for detailed product profiling.
- Clinical exploratory collaboration to identify biomarkers.



Liquid biopsy & profiling

- One-stop-shop center for liquid biopsy.
- Non-invasive paired biopsies utilized for a clinical sequencing to identify a time-course changes of molecular profile.
- New diagnostics technology development and implementation for clinical exploratory works.




Immuno-Genome Atlas

- Comprehensive atlas compiling, cancer genome, single cell assay of immune cells infiltrated in tumor immune microenvironment, and clinical findings.
- Immuno-Genome profiles available for not only major cancers, but also Asian prevalent cancers



J-PDX Library

- PDX library derived from Japanese patients has been established to support a compound screening and preclinical research.
- Prediction of clinical efficacy with an insights from PDX mice preclinical outcomes




Reverse TR: Sugu-yaru (Do it now!) Team

- Quick genome analysis and outcome return within 2 weeks for helping next therapy, when patients shows super-response or unexpected secondary resistance to molecular targeting drugs.
- Everything can be done immediately for patients in NCC under the master protocol 'Rainbow Cloud'.



NCC Bio Bank

- Remaining blood and tumor tissue (fresh frozen and FFPE) samples after a diagnosis and lab tests, have been collected from patients in the 2 NCC hospitals under the master consent.
- Associated medical information, treatment history, and clinical course can be utilized for a collaboration research.



Histopathology: Tissue Micro Array (TMA)

- Over 1000 FFPE tumor samples with brad cancer types including rare cancers are available for TMA.
- IHC and FISH would be effectively analyzed based on corresponding clinical information.

TR consultation and collaboration process

01

Drop a request to one-stop-shop contact for your TR consultation

The one-stop-shop contact is ready for your easy access, then you don't need to seek out appropriate researchers/physicians by yourselves.

02

Have a TR consultation meeting with pre-assigned researchers/physicians

Every TR consultation request is shared within the core members in a timely manner, then appropriate researchers/physicians should be pre-assigned from the board members. Confidentiality could be maintained within only limited attendees thus.

03

Conclude a joint research agreement

Having an agreement of TR plan at the consultation meeting, a joint research agreement would be concluded between customers and researchers/physicians in charge via NCC IP and Research Alliance Section.


04

Conduct TR study in collaboration across functions in NCC Tsukiji campus

Conduct TR study effectively in collaboration with NCCH clinical department, Fundamental Innovative Oncology Core and NCCRI research divisions.



TTRB organization



Your Contacts: Just drop any requests to us!



Hiroyuki Mano, M.D., Ph.D.

Director, NCC Research Institute

E-mail: hmano@ncc.go.jp



Noboru Yamamoto, M.D., Ph.D.

Deputy Director (Research), NCC Hospital

E-mail: nbryamam@ncc.go.jp



Kazunori Aoki, M.D., Ph.D.

Deputy Director, NCC Research Institute

E-mail: kaoki@ncc.go.jp



Yasushi Yatabe, M.D., Ph.D.

Chief, Diagnostic Pathology, NCC Hospital

E-mail: yyatabe@ncc.go.jp



Wakako Toga, Ph.D.

Deputy Director (R&D support),
NCC Research Institute

E-mail: wtoga@ncc.go.jp



TTRB